U.S. markets open in 6 hours 18 minutes

AngioDynamics, Inc. (ANGO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.33-0.16 (-0.63%)
At close: 4:00PM EDT
Sign in to post a message.
  • D
    Dieter
    Great achievement yesterday
  • a
    anthony
    This could be a hidden gem.
  • R
    Robert
    ANGO had a big move up yesterday and then had an increase in pre-market trading
  • B
    BAGHOLDER HUMPER
    Worth reading again and and again and again:

    https://www.medscape.com/viewarticle/850367

    ...because it is as close to a MIRACLE as you're likely ever to witness.
    In patients with locally advanced pancreatic cancer, irreversible ablation with the Nanoknife system doubles survival time compared with historical controls.
    In patients with locally advanced pancreatic cancer, irreversible ablation with the Nanoknife system doubles survival time compared with historical controls.
    www.medscape.com
  • D
    DC Dog
    Stagnant, minimal organic growth, limited R&D input to bottom line. Cost cutting at plant level continues, knowledge base eroding. No change in sight, a slow fall.
  • R
    Robert
    Beat on earnings and revenue. I assume this will be trending north today.
  • R
    Robert
    Down five cents on a terrible day following a significant increase. Nice product announcement and way off 52 week highs. Stock was hit by COVID-19 shutting down "non-essential" surgeries which are now back on-line. Hard to believe that the earnings announcement will not be generally positive.
  • R
    Robert
    Hopefully next month’s earnings puts the stock in position to make a run for $25 next year
  • B
    BAGHOLDER HUMPER
    Prospective investors should read THIS from the 2018 ASCO meeting:

    http://abstracts.asco.org/214/AbstView_214_224077.html

    Now, I'm not going into all of the details of what that means, but will note that it implies that the nanoknife COULD be used for conditions such as Peyronie's disease and Dupuytren's contracture. Look'em up!
    e23549 Safety and efficacy of irreversible electroporation for aggressive fibromatosis: Initial experience. Kyle Maughan, Ty Subhawong, Shree Venkat, Jonathan C. Trent; University of Miami School of Medicine, Miami Beach, FL, US; University of Miami
    e23549 Safety and efficacy of irreversible electroporation for aggressive fibromatosis: Initial experience. Kyle Maughan, Ty Subhawong, Shree Venkat, Jonathan C. Trent; University of Miami School of Medicine, Miami Beach, FL, US; University of Miami
    abstracts.asco.org
  • R
    Robert
    Raymond James increased price target to 18, which is the only news that I could find to account for this increase.
  • s
    stocktargetadvisor
    $ANGO
    Target Raised by Raymond James Financial Strong-Buy USD 18 » USD 24
    Target Raised by Canaccord Genuity Hold USD 14 » USD 18
  • B
    BAGHOLDER HUMPER
    I'm seeing an asked price of $23 -- something going on?
  • D
    Dieter
    Big potential
  • J
    JeffreyT
    Big volume and a nice move up in price today. Methinks there is more to come.
  • R
    Robert
    ANGO just exceeded its average daily trading volume. Someone is buying. Who?
  • r
    renita
    Just heard that ANGO got alerted at (http://tradenow.xyz). I hope it pushes us higher!
  • M
    Melanchroia
    I'm not sure what investors who bidded this up to $23.50 were expecting. Same old song and dance. Nanoknife has NOT been approved for a marketable indication. A study is required. It takes time even with the EAP. The best possibly near term catalyst is the sale of several divisions, i.e. "carve them out."
  • R
    Ron
    Is there a particular reason for the price increase?
  • f
    freeindeed
    History lesson - ANGO has missed qtrly earnings by a combined 18 cents in 10 years. Let that roll around in the grey matter for a couple of seconds. It's a solid play and who knows what it could do in the right hands.
  • D
    DC Dog
    Stagnant, minimal organic growth, limited R&D input to bottom line. Cost cutting at plant level continues, knowledge base eroding.